{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:28:16Z","timestamp":1790011696381,"version":"4.0.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education","doi-asserted-by":"publisher","award":["AICTE\/NDF\/53120"],"award-info":[{"award-number":["AICTE\/NDF\/53120"]}],"id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.phrs.2021.105484","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T02:34:04Z","timestamp":1616553244000},"page":"105484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"special_numbering":"C","title":["Epigenetics in NAFLD\/NASH: Targets and therapy"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3970-6417","authenticated-orcid":false,"given":"Nalini","family":"Sodum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-4875","authenticated-orcid":false,"given":"Gautam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Lalitha","family":"Bojja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-3954","authenticated-orcid":false,"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Mallikarjuna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105484_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17091379","article-title":"Micronutrient antioxidants and nonalcoholic fatty liver disease","volume":"17","author":"Chen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","article-title":"Preclinical Models for Studying NASH-Driven HCC: how useful are they?","volume":"29","author":"Febbraio","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2021.105484_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2019.11.015","article-title":"Physical exercise and liver \u201cfitness\u201d: role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease","volume":"32","author":"Stevanovi\u0107","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2021.105484_bib4","article-title":"The intersection of nonalcoholic fatty liver disease and obesity","volume":"8","author":"J.A.W","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2021.105484_bib5","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1210\/jc.2006-0587","article-title":"Review: the role of insulin resistance in nonalcoholic fatty liver disease","volume":"91","author":"Utzschneider","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105484_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrgastro.2013.34","article-title":"NAFLD in Asia -As common and important as in the West","volume":"10","author":"Farrell","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2021.105484_bib7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrd.2016.188","article-title":"Nonalcoholic steatohepatitis (NASH) drugs market","volume":"15","author":"Cassidy","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105484_bib8","first-page":"1","article-title":"Non-alcoholic fatty liver disease in Africa: a hidden danger","volume":"4","author":"Paruk","year":"2019","journal-title":"Glob. Heal. Epidemiol. Genomics."},{"key":"10.1016\/j.phrs.2021.105484_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20081948","article-title":"Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: an overview","volume":"20","author":"Marchisello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2021.105484_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091379","article-title":"Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease","volume":"17","author":"Chen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1478-3231.2007.01483.x","article-title":"Current concepts in the pathogenesis of nonalcoholic fatty liver disease","volume":"27","author":"M\u00e9ndez-S\u00e1nchez","year":"2007","journal-title":"Liver Int."},{"key":"10.1016\/j.phrs.2021.105484_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.129397","article-title":"SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1","volume":"4","author":"Crewe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2021.105484_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105484_bib14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2021.105484_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-016-0321-5","article-title":"Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease","volume":"15","author":"Paglialunga","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.phrs.2021.105484_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu10101383","article-title":"Regulation and metabolic significance of De Novo lipogenesis in adipose tissues","volume":"10","author":"Song","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2021.105484_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","article-title":"Role of cytokines and chemokines in non-alcoholic fatty liver disease","volume":"18","author":"Braunersreuther","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105484_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.619888","article-title":"Epigenetic regulation of adipogenesis in development of metabolic syndrome","volume":"8","author":"Pant","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2021.105484_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu9040387","article-title":"Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments","volume":"9","author":"Kitade","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2021.105484_bib20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.bbalip.2015.07.002","article-title":"Novel role of TLR4 in NAFLD development: Modulation of metabolic enzymes expression","volume":"1851","author":"Ferreira","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids."},{"key":"10.1016\/j.phrs.2021.105484_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106208","article-title":"Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice","volume":"80","author":"Liu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2021.105484_bib22","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/nu6083303","article-title":"Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition","volume":"6","author":"Lee","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2021.105484_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22020689","article-title":"Paternal methyl donor supplementation in rats improves fertility, physiological outcomes, gut microbial signatures and epigenetic markers altered by high fat\/high sucrose diet","volume":"22","author":"Chleilat","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib24","article-title":"Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg","volume":"2","author":"Fern\u00e1ndez-Barrena","year":"2020","journal-title":"JHEP Rep."},{"key":"10.1016\/j.phrs.2021.105484_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.5483\/BMBRep.2014.47.11.223","article-title":"Enzymatic DNA oxidation: mechanisms and biological significance","volume":"47","author":"Xu","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.phrs.2021.105484_bib26","first-page":"1","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Sookoian","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2021.105484_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mnfr.201000300","article-title":"Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet","volume":"55","author":"Tryndyak","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.phrs.2021.105484_bib28","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","article-title":"Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease","volume":"62","author":"Pirola","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2021.105484_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1053\/j.gastro.2013.07.047","article-title":"Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease","volume":"145","author":"Murphy","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2021.105484_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.phrs.2021.105484_bib31","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.3390\/ijms16035161","article-title":"Potential epigenetic mechanism in non-alcoholic fatty liver disease","volume":"16","author":"Sun","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"80","key":"10.1016\/j.phrs.2021.105484_bib32","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105484_bib33","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1074\/jbc.M311786200","article-title":"In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions","volume":"279","author":"Miao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105484_bib34","doi-asserted-by":"crossref","first-page":"26771","DOI":"10.1074\/jbc.M802800200","article-title":"Role of the histone H3 lysine 4 methyltransferase, SET7\/9, in the regulation of NF-\u03baB-dependent inflammatory genes: relevance to diabetes and inflammation","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105484_bib35","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1172\/JCI41624","article-title":"Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice","volume":"120","author":"Bricambert","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2021.105484_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41580-018-0076-0","article-title":"Integrative regulation of physiology by histone deacetylase 3","volume":"20","author":"Emmett","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105484_bib37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/liv.12534","article-title":"Non-alcoholic fatty liver disease: The role of nuclear receptors and circadian rhythmicity","volume":"34","author":"Mazzoccoli","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.phrs.2021.105484_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cmet.2007.08.014","article-title":"SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B","volume":"6","author":"Sun","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2021.105484_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/annotation\/b456329c-02fa-4055-afb8-2090cec17da6","article-title":"Immunopositivity for Histone MacroH2A1 Isoforms Marks Steatosis-Associated Hepatocellular Carcinoma","volume":"8","author":"Rappa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105484_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers9070090","article-title":"SIRT3: Oncogene and tumor suppressor in cancer","volume":"9","author":"Torrens-Mas","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2021.105484_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.molcel.2011.07.019","article-title":"SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome","volume":"44","author":"Hirschey","year":"2011","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2021.105484_bib42","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1074\/mcp.M115.050344","article-title":"Heterogeneous ribonucleoprotein K (hnRNP K) binds miR-122, a mature liver-specific microRNA required for hepatitis C virus replication","volume":"14","author":"Fan","year":"2015","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.phrs.2021.105484_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00592-010-0226-0","article-title":"Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study","volume":"48","author":"Kong","year":"2011","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2021.105484_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ijms19123966","article-title":"MiRNA signature in NAFLD: a turning point for a non-invasive diagnosis","volume":"19","author":"Dongiovanni","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells9081767","article-title":"MicroRNA-221: a fine tuner and potential biomarker of chronic liver injury","volume":"9","author":"Markovic","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2021.105484_bib46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/2211536607666180531093302","article-title":"Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD)","volume":"7","author":"Jampoka","year":"2018","journal-title":"MicroRNA"},{"key":"10.1016\/j.phrs.2021.105484_bib47","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.cellsig.2012.07.023","article-title":"The potential of microRNAs in liver fibrosis","volume":"24","author":"He","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.phrs.2021.105484_bib48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.diabres.2012.11.025","article-title":"Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease","volume":"99","author":"Zhang","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2021.105484_bib49","first-page":"1","article-title":"MicroRNAs as a novel tool in the diagnosis of liver lipid dysregulation and fatty liver disease","volume":"24","author":"Yu","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2021.105484_bib50","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.3390\/ijms14048437","article-title":"Dual role of microRNAs in NAFLD","volume":"14","author":"Ceccarelli","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12664-020-01021-2","article-title":"Treatment of non-alcoholic fatty liver disease \u2014 current perspectives","volume":"39","author":"Elhence","year":"2020","journal-title":"Indian J. Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105484_bib52","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10620-016-4153-y","article-title":"Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease","volume":"61","author":"Hannah","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.07.007","article-title":"Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease","volume":"181","author":"Jump","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2021.105484_bib54","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","article-title":"Treatment options for alcoholic and non-alcoholic fatty liver disease: a review","volume":"23","author":"Singh Sukhpreet","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105484_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.ijo.0800571","article-title":"Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty","volume":"22","author":"Scheen","year":"1998","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.phrs.2021.105484_bib56","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/cen.13303","article-title":"Effects of oral \u03b1-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial","volume":"86","author":"Li","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105484_bib57","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.endonu.2015.03.009","article-title":"The effect of polyunsaturated fatty acids on obesity through epigenetic modifications","volume":"62","author":"Hernando Boigues","year":"2015","journal-title":"Endocrinol. Nutr."},{"key":"10.1016\/j.phrs.2021.105484_bib58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12659\/MSM.881749","article-title":"SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease","volume":"17","author":"Colak","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.phrs.2021.105484_bib59","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1159\/000495898","article-title":"Resveratrol ameliorates lipid droplet accumulation in liver through a SIRT1\/ ATF6-dependent mechanism","volume":"51","author":"Zhou","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.phrs.2021.105484_bib60","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.bbadis.2017.08.004","article-title":"Ablation of systemic SIRT1 activity promotes nonalcoholic fatty liver disease by affecting liver-mesenteric adipose tissue fatty acid mobilization","volume":"1863","author":"Cheng","year":"2017","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.phrs.2021.105484_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15280\/jlm.2014.4.2.80","article-title":"SIRT3 as a regulator of non-alcoholic fatty liver disease","volume":"4","author":"Cho","year":"2014","journal-title":"J. Lifestyle Med."},{"key":"10.1016\/j.phrs.2021.105484_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1751-2980.2009.00416.x","article-title":"SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells","volume":"11","author":"Shi","year":"2010","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.phrs.2021.105484_bib63","article-title":"SIRT6 protects against liver fibrosis by deacetylation and suppression of SMAD3 in hepatic stellate cells","author":"Zhong","year":"2020","journal-title":"Am. Gastroenterol. Assoc."},{"key":"10.1016\/j.phrs.2021.105484_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2019.105667","article-title":"Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway","volume":"119","author":"Hosseini","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2021.105484_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21062084","article-title":"Potential adverse effects of resveratrol: a literature review","volume":"21","author":"Shaito","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib66","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tig.2020.03.003","article-title":"The epigenetic drug discovery landscape for metabolic-associated fatty liver disease","volume":"36","author":"Bayoumi","year":"2020","journal-title":"Trends Genet."},{"key":"10.1016\/j.phrs.2021.105484_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1592\/phco.22.1.123.33501","article-title":"Sexual dysfunction secondary to gemfibrozil","volume":"22","author":"James","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2021.105484_bib68","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.117.242081","article-title":"Pleiotropic and adverse effects of statins-do epigenetics play a role?","volume":"362","author":"Allen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2021.105484_bib69","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbalip.2016.12.005","article-title":"NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition","volume":"1862","author":"Mwinyi","year":"2017","journal-title":"Biochim. Biophys. Acta - Mol. Cell Biol. Lipids."},{"key":"10.1016\/j.phrs.2021.105484_bib70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200730030-00003","article-title":"Psychiatric adverse reactions with statins, fibrates and ezetimibe","volume":"30","author":"Tatley","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2021.105484_bib71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11596-019-1997-3","article-title":"Berberine ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats via activation of SIRT3\/AMPK\/ACC pathway","volume":"39","author":"pei Zhang","year":"2019","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib72","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/ptr.5693","article-title":"Berberis vulgaris and berberine: an update review","volume":"30","author":"Imenshahidi","year":"2016","journal-title":"Phyther. Res."},{"key":"10.1016\/j.phrs.2021.105484_bib73","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.13262","article-title":"Epigenetic effects of metformin: From molecular mechanisms to clinical implications","volume":"20","author":"Bridgeman","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2021.105484_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mehy.2017.07.009","article-title":"\u201cMetformin-resistant\u201d folic acid producing probiotics or folic acid against metformin\u2019s adverse effects like diarrhea","volume":"106","author":"Olgun","year":"2017","journal-title":"Med. Hypotheses."},{"key":"10.1016\/j.phrs.2021.105484_bib75","first-page":"1","article-title":"Supplementation with alpha-tocopherol and ascorbic acid to nonalcoholic fatty liver disease\u2019s statin therapy in men","author":"Hadzi-Petrushev","year":"2018","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu9060607","article-title":"Vitamin e modifies high-fat diet-induced increase of DNA strand breaks, and changes in expression and DNA methylation of DNMT1 and MLH1 in C57BL\/6J male mice","volume":"9","author":"Remely","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2021.105484_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17071166","article-title":"Tissue-specific effects of vitamin e supplementation","volume":"17","author":"Jansen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/carcin\/bgn270","article-title":"The carotenoid b -cryptoxanthin stimulates the repair of DNA oxidation damage in addition to acting as an antioxidant in human cells","volume":"30","author":"Lorenzo","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.phrs.2021.105484_bib79","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1111\/bph.15099","article-title":"Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21\/PGC-1\u03b1 pathway","volume":"177","author":"Wu","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105484_bib80","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/rda.12589","article-title":"Astaxanthin normalizes epigenetic modifications of bovine somatic cell cloned embryos and decreases the generation of lipid peroxidation","volume":"50","author":"Li","year":"2015","journal-title":"Reprod. Domest. Anim."},{"key":"10.1016\/j.phrs.2021.105484_bib81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cotox.2018.12.005","article-title":"Is Nrf2-ARE a potential target in NAFLD mitigation?","volume":"13","author":"Li","year":"2019","journal-title":"Curr. Opin. Toxicol."},{"key":"10.1016\/j.phrs.2021.105484_bib82","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-016-0926-5","article-title":"Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK","volume":"53","author":"Du","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.phrs.2021.105484_bib83","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1111\/jcmm.15139","article-title":"Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2\/AMPK\/mTOR signalling pathways","volume":"24","author":"Shen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2021.105484_bib84","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13300-016-0180-0","article-title":"Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review","volume":"7","author":"Ostawal","year":"2016","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2021.105484_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2018.00719","article-title":"glucagon like peptide 1 and micro RNA iacn metabolic diseases: focusing on GLP1 action on miRNAs","volume":"9","author":"Capuani","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105484_bib86","unstructured":"N.D. Reviews, Liraglutide (Saxenda) for Weight Loss, 2016."},{"key":"10.1016\/j.phrs.2021.105484_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5603\/DK.2017.0035","article-title":"Sitagliptin induced splenic infarcts","volume":"6","author":"Misgar","year":"2017","journal-title":"Clin. Diabetol."},{"key":"10.1016\/j.phrs.2021.105484_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110889","article-title":"Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: a review","volume":"132","author":"Patil","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105484_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21031113","article-title":"The epigenetics of the endocannabinoid system","volume":"21","author":"Meccariello","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib90","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.drugalcdep.2018.08.011","article-title":"Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist \/ CB2R agonist aminoalkylindole derivatives in mice","volume":"192","author":"Tai","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.phrs.2021.105484_bib91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.freeradbiomed.2012.10.525","article-title":"Seven sirtuins for seven deadly diseases ofaging","volume":"56","author":"Morris","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2021.105484_bib92","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1136\/gutjnl-2014-308430","article-title":"MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway","volume":"65","author":"Wu","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2021.105484_bib93","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/gutjnl-2011-300717","article-title":"MicroRNA-221\/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis","volume":"61","author":"Ogawa","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2021.105484_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2019.00279","article-title":"Regulatory non-coding RNAs network in non-alcoholic fatty liver disease","volume":"10","author":"Sulaiman","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2021.105484_bib95","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2021.105484_bib96","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/febs.12806","article-title":"Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease","volume":"281","author":"Ferreira","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2021.105484_bib97","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.aohep.2019.12.003","article-title":"Identification and study of differentially expressed miRNAs in aged NAFLD rats based on high-throughput sequencing","volume":"19","author":"Zhang","year":"2020","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.phrs.2021.105484_bib98","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/ijo.2017.21","article-title":"Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD","volume":"41","author":"Latorre","year":"2017","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.phrs.2021.105484_bib99","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/1348-0421.12154","article-title":"Chloroquine interferes with dengue-2 virus replication in U937 cells","volume":"58","author":"Farias","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.phrs.2021.105484_bib100","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1073\/pnas.1102281108","article-title":"miR-33a\/b contribute to the regulation of fatty acid metabolism and insulin signaling","volume":"108","author":"D\u00e1valos","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2021.105484_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgast-2016-000096","article-title":"Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease","volume":"3","author":"Mehta","year":"2016","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105484_bib102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/17474124.2016.1125290","article-title":"Circulating microRNAs in nonalcoholic fatty liver disease","volume":"10","author":"DiStefano","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2021.105484_bib103","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hep.27153","article-title":"Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia","volume":"60","author":"Ng","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2021.105484_bib104","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.12659\/MSM.901377","article-title":"MiR-149 compromises the reactions of liver cells to fatty acid via its polymorphism and increases non-alcoholic fatty liver disease (NAFLD) risk by targeting methylene tetrahydrofolate reductase (MTHFR)","volume":"23","author":"An","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.phrs.2021.105484_bib105","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbrc.2011.09.120","article-title":"High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis","volume":"414","author":"Ahn","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105484_bib106","first-page":"1905","article-title":"Microrna-199a-3p attenuates hepatic lipogenesis by targeting sp1","volume":"9","author":"Cheng","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.phrs.2021.105484_bib107","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.3748\/wjg.v12.i27.4369","article-title":"Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease","volume":"12","author":"Assy","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105484_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-13-140","article-title":"The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review","volume":"13","author":"Xiang","year":"2013","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.phrs.2021.105484_bib109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.13302","article-title":"Therapies in non- \u00ad alcoholic steatohepatitis (NASH)","volume":"37","author":"Oseini","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.phrs.2021.105484_bib110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jhep.2010.03.016","article-title":"Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis","volume":"53","author":"Anstee","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2021.105484_bib111","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2016.02.002","article-title":"Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis","volume":"64","author":"Xiang","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2021.105484_bib112","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1007\/s10620-018-5268-0","article-title":"Silybin alleviates hepatic steatosis and fibrosis in nash mice by inhibiting oxidative stress and involvement with the Nf-\u03baB pathway","volume":"63","author":"Ou","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105484_bib114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13543784.2020.1703948","article-title":"Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Ure","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105484_bib115","first-page":"1","article-title":"Scutellarin, a modulator of mTOR, attenuates hepatic insulin resistance by regulating hepatocyte lipid metabolism via SREBP-1c suppression","author":"Luan","year":"2019","journal-title":"Phytother. Res."},{"key":"10.1016\/j.phrs.2021.105484_bib116","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mam.2016.11.008","article-title":"Epigenetics in non-alcoholic fatty liver disease","volume":"54","author":"Lee","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.phrs.2021.105484_bib117","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13105-016-0492-6","article-title":"The role of sirtuins in cellular homeostasis","volume":"72","author":"Kupis","year":"2016","journal-title":"J. Physiol. Biochem."},{"issue":"13\u201314","key":"10.1016\/j.phrs.2021.105484_bib118","article-title":"Quantitative proteome-based systematic identification of SIRT7 substrates","volume":"17","author":"Zhang","year":"2017","journal-title":"Proteomics"},{"key":"10.1016\/j.phrs.2021.105484_bib119","doi-asserted-by":"crossref","first-page":"852","DOI":"10.7150\/ijbs.19370","article-title":"Emerging roles of SIRT1 in fatty liver diseases","volume":"13","author":"Ding","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.phrs.2021.105484_bib120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.gastro.2013.10.059","article-title":"Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2021.105484_bib121","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/ajpendo.90997.2008","article-title":"Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice","volume":"297","author":"Yamazaki","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105484_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0141227","article-title":"Green tea extract rich in epigallocatechin-3-gallate prevents fatty liver by AMPK activation via LKB1 in mice fed a high-fat diet","volume":"10","author":"Santamarina","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105484_bib123","first-page":"1","article-title":"Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:42:02Z","timestamp":1778794922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":123,"alternative-id":["S1043661821000682"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105484","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetics in NAFLD\/NASH: Targets and therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105484"}}